Hypersensitivity Pneumonitis Market Size, Share, Trends, Growth and Forecast 2030

Hypersensitivity Pneumonitis Industry Prospective:

The global hypersensitivity pneumonitis market size was worth around USD 876.94 million in 2022 and is predicted to grow to around USD 1254.83 million by 2030 with a compound annual growth rate (CAGR) of roughly 4.56% between 2023 and 2030.

Request Free Sample

Hypersensitivity Pneumonitis Market: Overview

Hypersensitivity pneumonitis is an immune system disorder. It affects the lungs that are inflated caused by an allergic reaction to inhaled animal proteins, plants, microorganisms, or some form of chemicals. Allergens causing hypersensitivity pneumonitis are naturally occurring including bird droppings, feathers, animal dander, or household mold. The severity of the condition may vary from case to case however, the most common form of hypersensitivity pneumonitis is the acute variant. Studies have shown that about 5% of people with acute conditions tend to develop chronic variants of this condition. With years of research and analysis, the scientific community has registered more than 300 substances that can act as an allergen causing the medical issue and hence the most commonly occurring cases have been given names that relate to the source of the condition. For instance, Farmer’s lung is witnessed in farmers since they are regularly exposed to straw, hay, and grain. Humidifier lung is caused by bacteria or fungus growing in air conditioners, humidifiers, and other heating or cooling systems. While being constantly exposed to allergens is a major reason causing hypersensitivity pneumonitis, genetics is also known to play a role as it increases the risk of contracting the disease.

Key Insights:

• As per the analysis shared by our research analyst, the global hypersensitivity pneumonitis market is estimated to grow annually at a CAGR of around 4.56% over the forecast period (2023-2030)
• In terms of revenue, the global hypersensitivity pneumonitis market size was valued at around USD 876.94 million in 2022 and is projected to reach USD 1254.83 million, by 2030.
• The hypersensitivity pneumonitis market is projected to grow at a significant rate due to the growing prevalence of the condition
• Based on source of exposure segmentation, occupational exposure was predicted to show maximum market share in the year 2022
• Based on diagnosis segmentation, the imaging tests segment was the leading segment in 2022
• On the basis of region, Asia-Pacific was the leading revenue generator in 2022

Request Free Sample

Hypersensitivity Pneumonitis Market: Growth Drivers

Rising cases of hypersensitivity pneumonitis to propel market growth

The global hypersensitivity pneumonitis market is projected to grow owing to the increasing prevalence of the disease influenced by changing environmental conditions and population lifestyles. A recent report by ATS Journals concluded that the 1-year prevalence rate of the disease may range from 1.67 to 2.71 per 100,000 persons. Since most of the allergens associated with the disease are naturally occurring, the risk of being exposed to a given allergen is relatively high and cannot be controlled. For instance, as reported by Thursday’s journal Science, the bird population in the US and Canada regions is over 7 billion. In addition to this, there has been a significant drop in the immunity level of the current population caused by several factors that include poor eating habits, sedentary lifestyle, and exposure or consumption of drugs, alcohol, and other toxic substances leaving them more vulnerable to reacting harshly to environmental factors.

Rise in elderly population to drive market growth

A large section of people diagnosed with hypersensitivity pneumonitis fall between the age group of 50 years to 55 years. The rising number of people approaching or falling in the age group can lead to an increased demand for medications and treatment related to the condition. Official statistics indicate that the population of people over 50 years is around 108 million and it is expected to continue growing in the coming decade.

Increased access to healthcare and rising awareness about the condition to create further revenue

Healthcare access on a global scale has increased significantly in recent times. This includes several allergy-testing facilities. In addition to this, with the increased efforts of the medical community and government healthcare units, awareness about the causes, diagnosis, and treatment of hypersensitivity pneumonitis has improved in developed and developing nations. There are more than 6000 hospitals in the US and over 200 Federal Government Hospitals as reported by the American Hospital Association.

Hypersensitivity Pneumonitis Market: Restraints

Incorrect or underdiagnosis of the condition could restrict market growth trend

The symptoms of hypersensitivity pneumonitis are similar to flu. It includes reactions such as shortness of breath, extreme tiredness, cough, chest pain, fever, chills, abnormal sound when breathing, and long-term bronchitis. These are extremely common symptoms that occur for almost all types of allergic reactions or medical conditions. Hence it becomes difficult to diagnose the correct underlying cause for the observed body reactions and the risk of misdiagnosing the disease increases.

High cost of medication and limited infrastructure in certain regions limit market growth possibilities

Diagnosis of the condition and subsequent medical treatment can be expensive. For instance, diagnosing the issue may require lung function tests, computed tomography (CT) scans, or bronchoscopy. Additionally, several regions lack the necessary treatment facilities or diagnostic infrastructure further leading to limited growth in the hypersensitivity pneumonitis industry.

Hypersensitivity Pneumonitis Market: Opportunities

Rising investment in research and development to create growth opportunities

Since the number of patients suffering from the condition has risen over the years, several healthcare and pharmaceutical companies have taken up research projects to improve understanding of the disease and diagnostic tools. This includes a thorough analysis of pathogen-inducing hypersensitivity pneumonitis and the identification of potential therapeutic targets. Moreover, the rising development of non-invasive approaches to disease diagnosis including breath analyzers and blood-based biomarkers may create further growth opportunities for the global market players. Other factors including increasing strategic partnerships between pharmaceutical players and integration of modern advanced technologies such as artificial intelligence in healthcare systems may work in favor of the current growth trend observed in the hypersensitivity pneumonitis industry.

Hypersensitivity Pneumonitis Market: Challenges

Absence of specific treatment and targeted therapies is a major challenge in the industry

One of the most crucial challenges faced by the global hypersensitivity pneumonitis market players is the absence of specific treatment or targeted therapies directed at managing and treating hypersensitivity pneumonitis. The preliminary treatment advice is to ensure not getting exposed to the specific allergen. However, in some cases, it is entirely impossible leading to depending on immunosuppressive medication or corticosteroids. Some patients have shown reactions to these medicines making treatment even difficult.

Hypersensitivity Pneumonitis Market: Segmentation

The global hypersensitivity pneumonitis market is segmented based on source of exposure, type, diagnosis, and region.

Based on source of exposure, the global market segments are occupational exposure, environmental allergens, drug-induced exposure, and others. In 2022, the highest growth was observed in the occupational exposure segment followed by environmental allergens. Occupational exposure is caused by people who are constantly exposed to certain allergens at their workplace. This may include farmers working on agricultural land or bird breeders who are exposed to avian proteins found in birds. Research indicates that the risk of occupation-induced hypersensitivity pneumonitis is as common as 1.4 per 100 people.

Based on type, the hypersensitivity pneumonitis industry segments are chronic hypersensitivity pneumonitis and acute hypersensitivity pneumonitis.

Based on diagnosis, the global market is divided into pulmonary function tests, imaging, tests, biopsy, and others. The highest growth was observed in the imaging segment of the hypersensitivity pneumonitis industry as it is one of the first diagnostic steps undertaken by medical professionals to either confirm hypersensitivity pneumonitis or rule out the other causes of the symptoms. In addition to this, they may also conduct pulmonary function tests to assess if the lung is functioning as expected or if there is any obstructed breathing. Biopsy is also one of the most significant revenue generators since it may be required in certain cases. On average, the average national cost of CT is between USD 300 to USD 6750 in the US.

Hypersensitivity Pneumonitis Market: Report Scope

Hypersensitivity Pneumonitis Market: Regional Analysis

North America to register the highest growth during the forecast period

The global hypersensitivity pneumonitis market is expected to witness the highest growth in North America with the US and Canada leading with the highest revenue share. The regional growth is projected to be the result of the existence of a robust healthcare infrastructure and the presence of a large chain of hospitals excelling in treating mild to severe conditions. In addition to this, access to medical care is higher in developed countries along with greater paying capacity. The nationwide health insurance policies covering occupational hazards have assisted in easing the process of undertaking medical assistance when required. Several dominating pharmaceutical companies are headquartered in the US which further assists in regional growth. They are constantly investing in research & development along with innovation toward novel therapies for existing medical diseases while preparing for future scenarios. In 2021, the US pharmaceutical industry was valued at over USD 500 billion and is known to account for close to 50% of the global pharmaceutical market. Europe is expected to grow at a rapid rate as there is a significant increase in the number of people over 50 years as well as a higher prevalence of the condition. The rising focus on further improving existing healthcare programs and surging patient awareness initiatives could create higher regional revenue during the forecast period.

Hypersensitivity Pneumonitis Market: Competitive Analysis

The global hypersensitivity pneumonitis market is led by players like:

• Johnson & Johnson Services Inc.
• F.Hoffmann-La Roche Ltd.
• Boehringer Ingelheim International GmbH
• AstraZeneca Plc.
• GlaxoSmithKline plc.
• Pfizer Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Novartis International AG
• Merck KGaA

The global hypersensitivity pneumonitis market is segmented as follows:

By Source of Exposure

• Occupational Exposure
• Environmental Allergens
• Drug-Induced Exposure
• Others

By Type

• Chronic Hypersensitivity Pneumonitis
• Acute Hypersensitivity Pneumonitis

By Diagnosis

• Pulmonary Function Tests
• Imaging Tests
• Biopsy
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa